Ocular hypotensive efficacy of Src-family tyrosine kinase inhibitors via different cellular actions from Rock inhibitors

Experimental Eye Research

Volumn 119, Issue , 2014, Pages 97-105

  Kirihara, Tomoko ^a,b   Shimazaki, Atsushi ^a   Nakamura, Masatsugu ^a   Miyawaki, Nobuaki ^a  

^a SANTEN PHARMACEUTICAL CO LTD   (Japan)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

Author keywords

Intraocular pressure; PP2; Rock; Src family tyrosine kinase; Trabecular meshwork

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 7 TERT BUTYL 5 (4 CHLOROPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; 4 AMINO 7 TERT BUTYL 5 (4 METHYLPHENYL)PYRAZOLO[3,4 D]PYRIMIDINE; COLLAGEN TYPE 1; DAMNACANTHAL; F ACTIN; FIBRONECTIN; FOCAL ADHESION KINASE; LAMININ 1; PROTEIN P130; VITRONECTIN;

ANIMAL EXPERIMENT; AQUEOUS HUMOR FLOW; ARTICLE; BASEMENT MEMBRANE; CELL ADHESION; CELL COUNT; CELL DEATH; CELL DENSITY; CELL MEMBRANE PERMEABILITY; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; ELECTRIC RESISTANCE; EXPERIMENTAL RABBIT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTRAOCULAR PRESSURE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; TRABECULAR MESHWORK; TRANSEPITHELIAL ELECTRICAL RESISTANCE;

INTRAOCULAR PRESSURE; PP2; ROCK; SRC-FAMILY TYROSINE KINASE; TRABECULAR MESHWORK;

ANIMALS; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MICROSCOPY, CONFOCAL; PYRAZOLES; PYRIMIDINES; RABBITS; RHO-ASSOCIATED KINASES; SRC-FAMILY KINASES; TRABECULAR MESHWORK;

EID: 84892447138     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2013.11.015     Document Type: Article

References (39)

1. Acott T.S., Kelley M.J. Extracellular matrix in the trabecular meshwork. Exp. Eye Res. 2008, 86:543-561.
2. Akaishi T., Ishida N., Shimazaki A., Hara H., Kuwayama Y. Continuous monitoring of circadian variations in intraocular pressure by telemetry system throughout a 12-week treatment with timolol maleate in rabbits. J.Ocul. Pharmacol. Ther. 2005, 21:436-444.
3. Ammar D.A., Kahook M.Y. Effects of glaucoma medications and preservatives on cultured human trabecular meshwork and non-pigmented ciliary epithelial cell lines. Br. J. Ophthalmol. 2011, 95:1466-1469.
4. Avizienyte E., Fincham V.J., Brunton V.G., Frame M.C. Src SH3/2 domain-mediated peripheral accumulation of Src and phosphor-myosin is linked to deregulation of E-cadherin and the epithelial-mesenchymal transition. Mol. Biol. Cell 2004, 15:2794-2803.
5. 2EDTA on permeability of human Schlemm's canal cell monolayers. Curr. Eye Res. 2004, 28:391-398.
6. Camras C.B., Hedman K., for the US Latanoprost Study Group Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J.Glaucoma 2003, 12:466-469.
7. Choplin N., Bernstein P., Batoosingh A.L., Whitcup S.M., for the Bimatoprost/Latanoprost Study Group Arandomized, investigator-masked comparison of diurnal responder rates with bimatoprost and latanoprost in the lowering of intraocular pressure. Surv. Ophthalmol. 2004, 49:S19-S25.
8. Coleman A.L., Miglior S. Risk factors for glaucoma onset and progression. Surv. Ophthalmol. 2008, 53:S3-S10.
9. Collaborative Normal-Tension Glaucoma Study Group Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am. J. Ophthalmol. 1998, 126:487-497.
10. Elliott J., Zheleznova N.N., Wilson P.D. c-Src inactivation reduces renal epithelial cell-matrix adhesion, proliferation, and cyst formation. Am. J. Physiol. Cell Physiol. 2011, 301:C522-C529.
11. Fincham V.J., Chudleigh A., Frame M.C. Regulation of p190 Rho-GAP by v-Src is linked to cytoskeletal disruption during transformation. J.Cell Sci. 1999, 112:947-956.
12. Fleenor D.L., Shepard A.R., Hellberg P.E., Jacobson N., Pang I.H., Clark A.F. TGFb2-induced changes in human trabecular meshwork: implications for intraocular pressure. Invest. Ophthalmol. Vis. Sci. 2006, 47:226-234.
13. Gabelt B.T., Kaufman P.L. Changes in aqueous humor dynamics with age and glaucoma. Prog. Retin. Eye Res. 2005, 24:612-637.
14. Goel M., Picciani R.G., Lee R.K., Bhattacharya S.K. Aqueous humor dynamics: a review. Open Ophthal. J. 2010, 4:52-59.
15. Hanke J.H., Gardner J.P., Dow R.L., Changelian P.S., Brissette W.H., Weringer E.J., Pollok B.A., Connelly P.A. Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. J.Biol. Chem. 1996, 271:695-701.
16. Harburger D.S., Calderwood D.A. Integrin signalling at a glance. J.Cell Sci. 2009, 122:159-163.
17. Honjo M., Tanihara H., Inatani M., Kido N., Sawamura T., Yue B.Y.J.T., Narumiya S., Honda Y. Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility. Investig. Ophthalmol. Vis. Sci. 2001, 42:137-144.
18. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J.Cell Sci. 2006, 119:3901-3903.
19. Johnstone M.A. Aqueous humor outflow system overview. Becker-Shaffer's Diagnosis and Therapy of the Glaucomas 2009, 25-46. Mosby, St. Louis. R.L. Stamper, M.F. Lieberman, M.V. Drake (Eds.).
20. Jones R.J., Avizienyte E., Wyke A.W., Owens D.W., Brunton V.G., Frame M.C. Elevated c-Src is linked to altered cell-matrix adhesion rather than proliferation in KM12C human colorectal cancer cells. Br. J. Cancer 2002, 87:1128-1135.
21. ® ophthalmic solution 0.1%). Folia Pharmacol. Jpn. 2012, 140:177-182.
22. Kass M.A., Gordon M.O., Gao F., Heuer D.K., Higginbotham E.J., Johnson C.A., Keltner J.L., Miller J.P., Parrish R.K., Wilson M.R., for the Ocular Hypertension Treatment Study Group Delaying treatment of ocular hypertension: the ocular hypertension treatment study. Arch. Ophthalmol. 2010, 128:276-287.
23. Li A.F., Tane N., Roy S. Fibronectin overexpression inhibits trabecular meshwork cell monolayer permeability. Mol. Vis. 2004, 10:750-757.
24. Lu Z., Overby D.R., Scott P.A., Freddo T.F., Gong H. The mechanism of increasing outflow facility by rho-kinase inhibition with Y-27632 in bovine eyes. Exp. Eye Res. 2008, 86:271-281.
25. Okka M., Tian B., Kaufman P.L. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys. Trans. Am. Ophthalmol. Soc. 2004, 102:251-257.
26. Peng F., Zhang B., Wu D., Ingram A.J., Gao B., Krepinsky J.C. TGFβ-induced RhoA activation and fibronectin production in mesangial cells require caveolae. Am. J. Physiol. Renal Physiol. 2008, 295:F153-F164.
27. Playford M.P., Schaller M.D. The interplay between Src and integrins in normal and tumor biology. Oncogene 2004, 23:7928-7946.
28. Quigley H.A. Number of people with glaucoma worldwide. Br. J. Ophthalmol. 1996, 80:389-393.
29. Quigley H.A. Glaucoma. Lancet 2011, 377:1367-1377.
30. Rao P.V., Deng P.F., Kumar J., Epstein D.L. Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632. Investig. Ophthalmol. Vis. Sci. 2001, 42:1029-1037.
31. Russ P.K., Kupperman A.I., Presley S.H., Haselton F.R., Chang M.S. Inhibition of RhoA signaling with increased Bves in trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2010, 51:223-230.
32. Santas A.J., Bahler C., Peterson J.A., Filla M.S., Kaufman P.L., Tamm E.R., Johnson D.H., Peters D.M. Effect of heparin II domain of fibronectin on aqueous outflow in cultured anterior segments of human eyes. Invest. Ophthalmol. Vis. Sci. 2003, 44:4796-4804.
33. The AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am. J. Ophthalmol. 2000, 130:429-440.
34. Thomas S.M., Brugge J.S. Cellular functions regulated by Src family kinases. Annu. Rev. Cell Dev. Biol. 1997, 13:513-609.
35. Tian B., Kaufman P.L. Effects of the Rho kinase inhibitor Y-27632 and the phosphatase inhibitor calyculin A on outflow facility in monkeys. Exp. Eye Res. 2005, 80:215-225.
36. Weinreb R.N. Glaucoma neuroprotection: what is it? Why is it needed?. Can. J. Ophthalmol. 2007, 42:396-398.
37. Weinreb R.N., Khaw P.T. Primary open-angle glaucoma. Lancet 2004, 363:1711-1720.
38. Williams R.D., Novack G.D., Haarlem T.V., Kopczynski C., on behalf of AR-12286 phase 2A study group Ocular hypotensive effect of the rho kinase inhibitor AR-12286 in patients with glaucoma and ocular hypertension. Am. J. Ophthalmol. 2011, 152:834-841.
39. Zhang M., Maddala R., Rao P.V. Novel molecular insights into RhoA GTPase-induced resistance to aqueous humor outflow through the trabecular meshwork. Am. J. Physiol. Cell Physiol. 2008, 295:C1057-C1070.